Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.88 USD | -8.57% | -6.80% | -13.25% |
Apr. 12 | Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating | MT |
Apr. 11 | Syncona agrees to sell stake in investee company for GBP7.4 million | AN |
Evolution of the average Target Price on Century Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Century Therapeutics, Inc.
Piper Sandler | |
Canaccord Genuity | |
JPMorgan Chase | |
HC Wainwright | |
Chardan Research | |
SVB Securities LLC | |
EF Hutton | |
Guggenheim | |
William Blair & Co. | |
SVB Leerink | |
BofA Securities |
EPS Revisions
- Stock Market
- Equities
- IPSC Stock
- Consensus Century Therapeutics, Inc.